Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates IFRX Bullish with a Setup Score of 57, net conviction 52, actionability 62. How the Setup Score works →
| Total Setup Score | 57 |
|---|---|
| Directional Bias | Bullish |
| Net Conviction | 52 |
| Actionability | 62 (in range) |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering f… Read full Trend Edge analysis →
| Current Price | $2.09 |
|---|---|
| Market Cap | $309M |
| Float | 98.1M |
| Shares Outstanding | 147.4M |
| Price/Sales (TTM) | 9,842.62 |
| vs. Analyst Target | +279.2% to analyst PT |
| Operating Margin (TTM) | 352965.00% |
| Revenue (TTM) | -$10,101 |
| Dividend Rate | None |
| Analyst Target Price | $7.92 (7 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | N/A | -$34.0M | -$812,474 | -$33.6M |
| 2021 | N/A | -$45.6M | -$791,258 | -$44.9M |
| 2022 | N/A | -$29.5M | -$627,008 | -$28.8M |
| 2023 | $63,089 | -$42.7M | -$469,173 | -$42.1M |
| 2024 | $165,789 | -$46.1M | -$3.2M | -$45.6M |
| 2025 | $29,331 | -$45.6M | -$7.2M | -$45.2M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2025 | $23,830 | -$12.3M |
| Dec 2025 | -$33,931 | -$10.6M |
| Mar 2026 | N/A | -$5.6M |
| Jun 2026 | N/A | -$10.6M |
| Insider Ownership | 2.9% |
|---|---|
| Institutional Ownership | 70.3% |
| Short Float | 9.6% |
| % of All Funds Holding | 0.70% |
| Number of Funds Holding | 62 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $1.99 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $1.55 | Medium-term trend |
| Weekly | 80-Week SMA | $1.36 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $1.95 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $1.63 | Near-term monthly trend |
| Monthly | 20-Month SMA | $1.43 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $1.80 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $0.90 | support | 1.13x | 4 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 1.11% | 0.41% | 58.33% | 9.95% | -5.11% |
| 1 Day | -0.08% | 0.11% | 50.00% | 12.68% | -13.58% |
| 1 Week | -0.65% | -1.34% | 47.22% | 20.83% | -23.08% |
| 2 Weeks | 3.43% | 0.71% | 52.78% | 179.19% | -91.61% |
| 1 Month | 3.96% | -2.75% | 48.57% | 138.58% | -92.17% |
Next earnings: October 25, 2026 (40 days away)
| Month | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Jan | -8.7% | 22.2% | 9 |
| Feb | -3.7% | 55.6% | 9 |
| Mar | -8.6% | 33.3% | 9 |
| Apr | 52.4% | 66.7% | 9 |
| May | -8.0% | 33.3% | 9 |
| Jun | -16.2% | 22.2% | 9 |
| Jul | 5.0% | 33.3% | 9 |
| Aug | 8.6% | 44.4% | 9 |
| Sep | -4.9% | 37.5% | 8 |
| Oct | 2.5% | 50.0% | 8 |
| Nov | 8.8% | 50.0% | 8 |
| Dec | 8.5% | 66.7% | 9 |
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.10% | 43.1% | 415 |
| Tuesday | 0.77% | 44.5% | 458 |
| Wednesday | -0.15% | 46.0% | 454 |
| Thursday | 0.06% | 45.1% | 446 |
| Friday | 0.23% | 46.3% | 445 |
Institutional holder breakdown coming soon.
Total institutional ownership: 70.3%
Total insider ownership: 2.9%
Founder-led management: Niels Riedemann (Chief Executive Officer and Founder), Renfeng Guo (Chief Scientific Officer and Founder)
Full insider transaction history and smart buy/sell sentiment summary available on Trend Edge.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for InflaRx N.V. (IFRX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for IFRX on Trend Edge →